Zolinza

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Cutaneous, CTAGE1 protein, human

Treatment

5 FDA approvals

4 Active Studies for Zolinza

Treatment for

Lymphoma, T-Cell, Cutaneous

What is Zolinza

VorinostatThe Generic name of this drug

Treatment SummaryVorinostat (also known as suberoylanilide hydroxamic acid or SAHA) is a medication used to treat cutaneous T cell lymphoma (CTCL), a type of skin cancer. It works by blocking a protein called histone deacetylase. Studies have also suggested that vorinostat may be effective in treating a type of brain tumor called glioblastoma multiforme. More research is being done to determine the effectiveness of using vorinostat in combination with other drugs.

Zolinzais the brand name

image of different drug pills on a surface

Zolinza Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Zolinza

Vorinostat

2006

Approved as Treatment by the FDA

Vorinostat, otherwise called Zolinza, is approved by the FDA for 5 uses like progressive Cutaneous T-cell lymphoma and Cutaneous T-Cell Lymphoma Recurrent .

progressive Cutaneous T-cell lymphoma

Helps manage progressive Cutaneous T-cell lymphoma

Cutaneous T-Cell Lymphoma Recurrent

Helps manage Cutaneous T-Cell Lymphoma Recurrent

CTAGE1 protein, human

Helps manage Cutaneous T-Cell Lymphoma Recurrent

Lymphoma, T-Cell, Cutaneous

Helps manage progressive Cutaneous T-cell lymphoma

Lymphoma, T-Cell, Cutaneous

Helps manage persistent Cutaneous T-Cell Lymphoma

Effectiveness

How Zolinza works in the bodyVorinostat stops a group of enzymes, called histone deacetylases, from working. These enzymes usually remove acetyl groups from histone proteins. In some cancer cells, there are too many of these enzymes, leading to the suppression of certain cell processes. By blocking the action of these enzymes, Vorinostat helps to restore normal cell function and can help to stop the spread of cancer. The exact way this drug works is not completely understood.

When to interrupt dosage

The prescribed measure of Zolinza is based on the diagnosed condition, such as CTAGE1 protein, human, progressive Cutaneous T-cell lymphoma and Lymphoma, T-Cell, Cutaneous. The quantity of dosage fluctuates, in accordance with the approach of administration recorded in the table underneath.

Condition

Dosage

Administration

Lymphoma, T-Cell, Cutaneous

, 100.0 mg

, Oral, Capsule, Capsule - Oral

Lymphoma, T-Cell, Cutaneous

, 100.0 mg

, Oral, Capsule, Capsule - Oral

CTAGE1 protein, human

, 100.0 mg

, Oral, Capsule, Capsule - Oral

Warnings

There are 20 known major drug interactions with Zolinza.

Common Zolinza Drug Interactions

Drug Name

Risk Level

Description

2-Methoxyethanol

Major

The risk or severity of adverse effects can be increased when Vorinostat is combined with 2-Methoxyethanol.

9-(N-methyl-L-isoleucine)-cyclosporin A

Major

The risk or severity of adverse effects can be increased when Vorinostat is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.

Abetimus

Major

The risk or severity of adverse effects can be increased when Vorinostat is combined with Abetimus.

Acteoside

Major

The risk or severity of adverse effects can be increased when Vorinostat is combined with Acteoside.

Afelimomab

Major

The risk or severity of adverse effects can be increased when Vorinostat is combined with Afelimomab.

Zolinza Novel Uses: Which Conditions Have a Clinical Trial Featuring Zolinza?

5 active clinical trials are currently assessing the effectiveness of Zolinza in treating Lymphoma, Human CTAGE1 Protein, Cutaneous T-Cell, and Progressive Cutaneous T-Cell Lymphoma.

Condition

Clinical Trials

Trial Phases

Lymphoma, T-Cell, Cutaneous

0 Actively Recruiting

CTAGE1 protein, human

3 Actively Recruiting

Phase 2

Lymphoma, T-Cell, Cutaneous

0 Actively Recruiting

Patient Q&A Section about zolinza

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How is Vorinostat administered?

"Vorinostat is a capsule that is taken orally, typically once a day with food. Your doctor will tell you if you should take it every day or only certain days of the week. You should take vorinostat at approximately the same time each day."

Answered by AI

Is vorinostat FDA approved?

"The U.S. Food and Drug administration approved vorinostat for the treatment of skin manifestations of cutaneous T-cell lymphoma in patients who are unresponsive to other treatments. This is the first time a histone deacetylase inhibitor has been approved for any use in the United States."

Answered by AI

What is zolinza used for?

"ZOLINZA is a drug used to treat a type of cancer called cutaneous T-cell lymphoma (CTCL). CTCL is a cancer that affects the blood cells and causes skin problems. ZOLINZA is used when the cancer gets worse, does not go away, or comes back after you have taken other medicines."

Answered by AI